Medical Instrument Development Laboratories, Inc. (MID Labs) Obtains FDA 510(k) Clearance for Bi-Blade™ Vitrectomy Cutter

The new MID Labs Bi-Blade™ Vitrectomy Cutter increases surgical efficiency by adding twice the amount of cutting action per pulse actuation.

July 29, 2016

SAN LEANDRO, Calif. -- MID Labs, a leading global medical device company, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance for a new vitrectomy cutter that uses proprietary cutter technology to help enhance the clinical experience during this important procedure.

“We are pleased to announce the global launch of the new MID Labs Bi- Blade™ Vitrectomy Cutter, as MID Labs has now received both 510(k) clearance and CE mark approval of this new and innovative product” stated Dr. Kai Chen, President and CEO of MID Labs, Inc. “The Bi- Blade™ is the newest member of the MID Labs vitrectomy cutter family of products, and demonstrates MID Labs commitment to provide more efficient and effective technology to the Ophthalmology community.””

The MID Labs Bi-Blade™ Vitrectomy Cutter has an additional cutting edge which allows for a 2x increase in the amount of vitreous material that is cut in a single motion, effectively doubling the number of cuts (8000 cpm x 2) that can be performed in the same amount of time with no additional impact on retinal traction. The addition of a second port provides for a consistent aspiration flow rate and enhanced intraoperative fluidics stability. The MID Labs Bi-Blade™ Vitrectomy Cutter allows the surgeon to perform procedures using smaller gauge instruments while still maintaining the flow rates that are seen with conventional cutters.

The new MID Labs Bi-Blade™ Vitrectomy Cutter provides enhanced performance, improved surgical control, and increased surgical efficiency.

About MID Labs

MID Labs has been in business since 1981. Since that time, MID Labs has been a leader in vitrectomy and ophthalmic surgical equipment. As a company, it has been instrumental in revolutionizing the ophthalmic field through its new products. MID Labs continues to innovate with the MID Labs branded product line which is supplied to more than 30 countries around the world. These products set the standard for precision, performance, and quality. In addition, MID Labs serves its corporate customers with products and contract manufacturing services. For more information on MID Labs, please visit www.midlabs.com.


MID Labs Closed a $51MM Round of Financing Led by OrbiMed and Frontline BioVentures

October 16, 2014

SAN LEANDRO, Calif. -- MID Labs Ltd., a medical device company currently focused on developing novel products for vitreoretinal surgery, today announced the closing of $51 million of financing. This investment is led by OrbiMed and Frontline BioVentures. Other investors include Softbank China Venture Capital (SBCVC), Allen Chao, and Sungent BioVenture.

“MID Labs is well-positioned to leverage its technology leadership in vitrectors and broaden its product lines and commercialization capabilities on a global basis,” said Dr. Kai Chen, Chief Executive Officer of MID Labs. “In addition, we plan to use some of the proceeds from this financing to expand our development and production capacity both in the US and in China.”

“We look forward to working with the MID Labs team to realize its potential of innovation capability, efficient manufacturing, and expansion in China,” said Dr. David Wang, Senior Managing Director at OrbiMed.

About MID Labs

MID Labs was founded by Dr. Carl Wang in 1981 and has been associated with vitreoretinal surgery from its infancy. Not only has MID Labs invented the tools for modern vitrectomy, but as a company, it has been instrumental in revolutionizing the ophthalmic field through its new products. MID Labs continues to innovate with the MID Labs branded product line which is supplied to more than 30 countries around the world. These products set the standard for precision, performance, and quality. In addition, MID Labs serves its corporate customers with products and contract manufacturing services.

About OrbiMed

OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector, with approximately $12 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed's team of more than 80 employees manages a series of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. OrbiMed maintains its headquarters in New York City, with additional offices in Herzliya, San Francisco, Shanghai and Mumbai.